Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Shares of Novo Nordisk slipped in Monday morning trading ... a synthetic version of the hormone amylin, which is released by the pancreas. Cagrilintide is currently being developed in combination ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...